Pharmaceutical compositions comprising, as active ingredients, a mixture of: a) hyaluronic acid or salts thereof selected from sodium or potassium salts b) a bradykinin B2 receptor antagonist together with pharmaceutically acceptable carriers or excipients, in which: the hyaluronic acid is in the form of a polymer with an average MP of between 0.5 and 10 million daltons, and the bradykinin antagonist is selected from: - B2 receptor antagonists, selected from the group of: - HD-Arg-Arg- Pro-Hyp-Gly-Igl-Ser-D-F5F-Igl-Arg-OH - H-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-Igl-Oic-Arg-OH - HD-Arg- Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (Icatibant) - 4- [2 - [([[3- (3-Bromo-2-methyl-imidazo [1,2 -a] pyridin-8-yl oxymethyl) -2,4-dichloro-phenyl] -methyl-carbamoyl] -methyl) carbamoyl] -vinyl] -N, N-dimethyl-benzamide, - 3- (6-Acetylamino-pyridin -3-yl) -N - ([[2,4-dichloro-3- (2-methylquinolin-8-yl oxymethyl) -phenyl] -methyl-carbamoyl] -methyl) acrylamide, [3- (4-Carbamidoyl- benzoylamino) -propyl] -ami gives 1- [2,4-dichloro-3- (2,4-dimethyl-quinolin-8-yl oxymethyl) -benzene sulfonyl] -pyrrolidine-2-carboxylic acid, (Anatibant) 4- (4- [1- [2,4-Dichloro-3- (2,4-dimethyl-quinoline-8-yl oxymethyl) -benzene sulfonyl] -pyrrolidine-2-carbonyl] piperazine-1-carbonyl) -benzamidine, 2- [5- (4 -Cyan-benzoyl) -1-methyl-1H-pyrrole-2-yl] -N- [2,4-dichloro-3- (2-methyl-quinoline-8-yl oxymethyl) -phenyl] -Nmethyl-acetamide, - B2 receptor antagonists, which have the general formula (I) in which - R is hydrogen or methyl - W represents a single bond or an atom of O - n = 3, 4 - X is hydrogen or a group -NR1R2 amino wherein R1 and R2 can be, independently of each other, hydrogen or a group selected from methyl, ethyl, n-propyl, isopropyl, - Y is a quaternary ammonium (-NR3R4R5) + A- in which R3, R4, R5 may, be independent of each other, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, n-pentyl and A- is an anion of a pharmaceutically acceptable acid； its pharmacologically acceptable salts, enanti
